U.S., July 18 -- ClinicalTrials.gov registry received information related to the study (NCT07071090) titled 'A Phase 1 Study of DC50292A Tablet in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors' on July 08.
Brief Summary: This study employs a non-randomized, open-label design to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of DC50292A tablets in patients with MTAP-deficient advanced or metastatic solid tumors. The study consists of two parts: dose escalation and dose expansion.
Study Start Date: June 30
Study Type: INTERVENTIONAL
Condition:
Solid Tumor Malignancies
Intervention:
DRUG: DC50292A
DC50292A tablet
Recruitment Status: RECRUITING
Sponsor: Heronova Pharmaceutica...